William Blair downgraded Dynavax (DVAX) to Market Perform from Outperform after Sanofi (SNY) announced it will acquire the company for $15.50 per share. The analyst, who believes the acquisition “makes sense” given growing regulatory concerns around vaccines and investor questions on management’s strategy for value creation, calls Sanofi a “logical acquisition partner.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DVAX:
- Morning Movers: Intel slipping ahead of holiday shortened-session
- Dynavax jumps 37% to $15.31 after buyout offer from Sanofi
- Sanofi to acquire Dynavax for $15.50 per share in cash, or $2.2B
- Sanofi (SNY) Acquires Dynavax in $2.2 Billion Deal after FDA Rebuff
- Dynavax Technologies Reports Strong Q3 Earnings and Strategic Growth